Press Releases Archives - Page 27 of 103 - Lupin

BSE 2305.05 NSE 2301.50

indian flag icon

India

USA

great-britain flag icon

UK

south-africa flag icon

South Africa

australia flag icon

Australia

philippines flag icon

Philippines

germany flag icon

Germany

netherlands flag icon

Netherlands

mexico flag icon

Mexico

brazil flag icon

Brazil

canada flag icon

Canada

Switzerland flag icon

Switzerland

BSE 2305.05 NSE 2301.50

Lupin Receives Approval from US FDA for Glycopyrrolate Injection, USP

February 9, 2023

Lupin Launches Aptivate Champion Run for Kids Promoting Well-being and Good Eating Habits

February 3, 2023

Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets

January 31, 2023

Lupin Launches LYFE, its Digital Therapeutic Solution for Holistic Heart Care

January 24, 2023

Lupin Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients

January 18, 2023

Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets

January 16, 2023

Lupin Receives Approval from U.S. FDA for Prasugrel Tablets, USP

January 10, 2023

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders

January 9, 2023

Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets

January 6, 2023

Lupin Launches novel fixed-dose triple drug combination DIFIZMA® DPI to Treat Inadequately Controlled Asthma

January 5, 2023

1 2 … 26 27 28 … 102 103

Search

Hit enter to search or ESC to close